Embodiments in accordance with the present invention encompass an organoruthenium compound of the formula (I) or formula (II): ##STR00001##
Wherein X, L, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, Ar.sub.1 and Ar.sub.2 are as defined herein. Also disclosed herein are the use of organoruthenium compound of formula (I) or formula (II) as (pre)catalysts for the olefin metathesis reactions, as well as to the process for carrying out the olefin metathesis reaction.

Embodiments in accordance with the present invention encompass an organoruthenium compound of the formula (I) or formula (II): ##STR00001##
Wherein X, L, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, Ar.sub.1 and Ar.sub.2 are as defined herein. Also disclosed herein are the use of organoruthenium compound of formula (I) or formula (II) as (pre)catalysts for the olefin metathesis reactions, as well as to the process for carrying out the olefin metathesis reaction.

The present invention provides AHR agonists, compositions thereof, and methods of using the same.

The present invention provides AHR agonists, compositions thereof, and methods of using the same.

The present invention relates to novel 2,5,6-benzimidazole derivatives and pharmaceutically acceptable salts thereof. Another aspect of the invention relates to methods of treating a patient infected by Mycobacterium tuberculosis by administering to the patient a 2,5,6-benzimidazole derivative or a pharmaceutically acceptable salt thereof.

Provided is a compound of Formula (I):

##STR00001## wherein the variable groups are defined herein.

Provided is a compound of Formula (I):

##STR00001## wherein the variable groups are defined herein.

Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.

Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.

A process for removing impurities from a liquid azole heteroaromatic compound-containing (e.g., triazole-containing) mixture by: (a) providing a liquid azole heteroaromatic compound-containing mixture having impurities; and (b) passing the azole heteroaromatic compound-containing mixture through at least one filtration membrane which is a nanofiltration membrane and/or ultrafiltration membrane having a molecular pore size in the range of from about 200 daltons to about 1 kilodaltons to provide a permeate that is an at least partially purified azole heteroaromatic compound-containing mixture and a retentate with at least some impurities.